Entry |
|
Name |
Abciximab (USAN/INN); Abciximab (genetical recombination) (JAN); Reopro (TN) |
Formula |
C2109H3243N553O674S15
|
Exact mass |
47580.2300
|
Mol weight |
47609.62
|
Class |
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
DG01811 Fibrinogen receptor antagonist
|
Remark |
|
Efficacy |
Platelet aggregation inhibitor, Glycoprotein IIb/IIIa receptor antagonist |
Type |
Monoclonal antibody |
Target |
|
Pathway |
|
Interaction |
|
Structure map |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC13 Abciximab
D02778 Abciximab (USAN/INN)
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
D02778 Abciximab
DG01811 Fibrinogen receptor antagonist
D02778 Abciximab
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: other families
Integrins
ITGA2B/ITGB3
D02778 Abciximab (USAN/INN)
|
Other DBs |
|
LinkDB |
|